Takeaways from discussions on the Trump administration’s drug price controls with leaders at last week’s Association for Accessible Medicines’ Access 2026 conference With all of the chatter on the Web, including in BR&R, on the policy and legislative actions that affect biosimilars, we were eager to hear from some very smart people on the direct-to-patient … Continue reading Deeper Views on TrumpRx (the Direct-to-Patient Channel), MFN and MFP, and Biosimilars